Stock events for Gilead Sciences, Inc. (GILD)
Over the past six months, Gilead Sciences' stock has seen a positive performance, with increases of 25.10% and 28.04%. As of March 6, 2026, the stock price was $143.92 per share, a 22.58% increase over the past year. Key events include Q3 2025 financial results, where Gilead raised its full-year profit guidance despite a drop in Veklury sales, and Q4 2025 financial results, where Gilead exceeded earnings and revenue forecasts due to strong HIV treatment sales. Gilead issued 2026 guidance projecting product sales of $29.6 billion to $30 billion and non-GAAP diluted EPS of $8.45 to $8.85. Additionally, Gilead acquired Arcellx for $7.8 billion to gain full control of Anito-Cel.
Demand Seasonality affecting Gilead Sciences, Inc.’s stock price
While there is no explicit statement detailing overall demand seasonality, sales of Veklury, Gilead's COVID-19 treatment, experienced a significant drop in Q3 2025 due to lower COVID-19 hospitalizations, indicating demand is tied to COVID-19 prevalence. HIV product sales have shown consistent growth, suggesting a more stable demand, while liver disease treatments also contributed to growth. The demand for oncology products does not appear to be explicitly seasonal.
Overview of Gilead Sciences, Inc.’s business
Gilead Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for life-threatening diseases. The company researches and develops antiviral drugs for conditions such as HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, and has expanded into oncology, hematology, inflammatory, and respiratory diseases. Major products include HIV and antiviral therapies, liver disease treatments, oncology drugs, and other treatments like Veklury for COVID-19.
GILD’s Geographic footprint
Gilead Sciences operates globally, marketing its products through commercial teams, third-party distributors, and corporate partners, with a business presence in the U.S., Europe, and other international markets. Its headquarters and most administrative, manufacturing, and R&D activities are in Foster City, California, with other U.S. facilities in Oceanside, Seattle, El Segundo, La Verne, Oceanside, San Dimas, and Emeryville. Gilead also has an R&D and manufacturing site in Edmonton, Alberta, Canada, and operates in over 35 countries worldwide. The International region shows an upward trajectory in efficient asset utilization from 2021 to 2025.
GILD Corporate Image Assessment
Gilead Sciences has shown a strong improvement in its brand reputation in Asia, securing top spots in rankings for Australia, New Zealand, and China. Globally, Gilead was recognized as a strong player, ranking second among 15 Big Pharma companies. Gilead was also recognized as one of TIME's 100 Most Influential Companies for its work on lenacapavir, an anti-HIV drug, and its commitment to ensuring access to the drug in low and middle-income countries.
Ownership
Gilead Sciences is a publicly traded company with ownership distributed among shareholders, with institutional investors owning approximately 87.49% of the company's shares. Individual investors and Gilead Sciences insiders hold 11.39% and 1.11% respectively. Major institutional owners include BlackRock Inc., Vanguard Group Inc., and Fmr LLC.
